Product Information
XCOPRI 200 MG TABLET is a brand product labeled by SK Life Science, Inc., priced at $39.8775 per EA under NDC 71699020030. Its NADAC has been published 285 times since Apr 21, 2021.
FDA first approved this application on Mar 10, 2020.
Strength
200 mg/1
Manufacturer
SK Life Science, Inc.NDC
71699020030
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CENOBAMATEApproval Type
New Drug (NDA)
FDA Application
NDA212839FDA Approved
3/10/2020
On Market Since
3/12/2020
Pharmacological Classes
Price Statistics
The NADAC for XCOPRI 200 MG TABLET has been published 285 times since Apr 21, 2021, and over the history we have for it it has risen 21.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $39.8775 per EA |
|---|---|
| All-time high | $39.9414 (May 13, 2026) |
| All-time low | $32.9067 (Apr 21, 2021) |
| 52-week high | $39.9414 |
| 52-week low | $38.7702 |
| Median price | $37.6639 |
| Average price | $36.4903 |
| Largest weekly change | +6.0% (Jan 3, 2024) |
| Weeks tracked | 285 |
| Tracking since | Apr 21, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cenobamate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SK Life Science, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cenobamate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XCOPRI 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XCOPRI 200 MG TABLET, manufactured by SK Life Science, Inc., is $39.8775 per EA (NDC 71699020030), effective Sep 30, 2026.
How has the price of XCOPRI 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for XCOPRI 200 MG TABLET has risen 21.2%. It has been tracked across 285 weekly CMS publications since Apr 21, 2021.
What are the highest and lowest recorded NADAC prices for XCOPRI 200 MG TABLET?
Since Apr 21, 2021, the NADAC for XCOPRI 200 MG TABLET has ranged from a low of $32.9067 (Apr 21, 2021) to a high of $39.9414 (May 13, 2026), with a median of $37.6639 per EA.
Are there cheaper alternatives to XCOPRI 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XCOPRI 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XCOPRI 200 MG TABLET?
XCOPRI 200 MG TABLET (NDC 71699020030) is labeled by SK Life Science, Inc., and CMS classifies it as a brand product.